CA2457632C - Identification and isolation of somatic stem cells and uses thereof - Google Patents

Identification and isolation of somatic stem cells and uses thereof Download PDF

Info

Publication number
CA2457632C
CA2457632C CA2457632A CA2457632A CA2457632C CA 2457632 C CA2457632 C CA 2457632C CA 2457632 A CA2457632 A CA 2457632A CA 2457632 A CA2457632 A CA 2457632A CA 2457632 C CA2457632 C CA 2457632C
Authority
CA
Canada
Prior art keywords
cells
cell
ace
stem cells
stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2457632A
Other languages
English (en)
French (fr)
Other versions
CA2457632A1 (en
Inventor
Paul John Simmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast Inc
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Publication of CA2457632A1 publication Critical patent/CA2457632A1/en
Application granted granted Critical
Publication of CA2457632C publication Critical patent/CA2457632C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
CA2457632A 2001-08-15 2002-08-15 Identification and isolation of somatic stem cells and uses thereof Expired - Fee Related CA2457632C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR7036 2001-08-15
AUPR7036A AUPR703601A0 (en) 2001-08-15 2001-08-15 Identification and isolation of somatic stem cells and uses thereof
PCT/AU2002/001101 WO2003016916A1 (en) 2001-08-15 2002-08-15 Identification and isolation of somatic stem cells and uses thereof

Publications (2)

Publication Number Publication Date
CA2457632A1 CA2457632A1 (en) 2003-02-27
CA2457632C true CA2457632C (en) 2014-07-15

Family

ID=3830992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2457632A Expired - Fee Related CA2457632C (en) 2001-08-15 2002-08-15 Identification and isolation of somatic stem cells and uses thereof

Country Status (9)

Country Link
US (1) US7718376B2 (https=)
EP (1) EP1432991B1 (https=)
JP (1) JP4922548B2 (https=)
AT (1) ATE543098T1 (https=)
AU (2) AUPR703601A0 (https=)
CA (1) CA2457632C (https=)
ES (1) ES2381183T3 (https=)
IL (2) IL160394A0 (https=)
WO (1) WO2003016916A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
WO2004069172A2 (en) 2003-01-30 2004-08-19 The Government of the United States of America as represented by the Department of Veterans Affairs Multilineage-inducible cells and uses thereof
CN100377165C (zh) * 2003-04-24 2008-03-26 皇家飞利浦电子股份有限公司 无创式左心室的容积测定
EP1656443A4 (en) * 2003-05-02 2007-06-06 Sigma Aldrich Co SOLID PHASE CELLYSIS AND IMPACT PLATFORM
RU2271818C1 (ru) * 2004-08-18 2006-03-20 ЗАО "РеМеТэкс" Биотрансплантат, способ его получения и способ лечения косметических дефектов кожи (варианты)
RU2271817C1 (ru) * 2004-08-18 2006-03-20 ЗАО "РеМеТэкс" Биотрансплантат и способ лечения легочной гипертензии
RU2271819C1 (ru) * 2004-08-18 2006-03-20 ЗАО "РеМеТэкс" Биотрансплантат, способ его получения (варианты) и способ лечения алопеции
RU2272638C1 (ru) * 2004-08-18 2006-03-27 ЗАО "РеМеТэкс" Биотрансплантат, способ его получения и способ лечения хронического гепатита и цирроза печени (варианты)
EP1870455A4 (en) * 2005-03-31 2010-01-20 Two Cells Co Ltd METHOD FOR DISTINCTION OF MESENCHYMAL STEM CELL USING MOLECULAR MARKER AND USE THEREOF
EP1976878A4 (en) * 2006-01-30 2010-06-02 Fred Hutchinson Cancer Res Fou FOLLOW OF THE VARIABLE STRO-1 ANTIBODY REGION
US20080025953A1 (en) * 2006-07-25 2008-01-31 Kiminobu Sugaya Vigor Enhancement of Animals Via Administration of Stem Cells
US9487756B2 (en) * 2009-03-20 2016-11-08 Mesoblast, Inc. Production of reprogrammed pluripotent cells
ES2609006T3 (es) * 2009-10-16 2017-04-18 Rutgers, The State University Of New Jersey Procedimeinto de tratamiento de lesión crónica de tejido nervioso usando una estrategia de terapia celular
US9081008B2 (en) 2009-12-04 2015-07-14 James Sherley Detecting and counting tissue—specific stem cells and uses thereof
US8759098B2 (en) 2009-12-04 2014-06-24 Boston Biomedical Research Institute, Inc. Method for cloning pluripotent stem cells
WO2011069121A1 (en) * 2009-12-04 2011-06-09 Neostem, Inc. Mesenchymal stem cells (mscs) isolated from mobilized peripheral blood
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP6017845B2 (ja) * 2011-06-10 2016-11-02 帝人ファーマ株式会社 Ｇｐｉアンカータンパク質欠損細胞の検出方法
CN104508124B (zh) 2011-07-06 2017-11-17 细胞治疗有限公司 中胚层谱系祖细胞
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CN105866432B (zh) * 2016-05-11 2018-01-26 天津欣普赛尔生物医药科技有限公司 用于鉴定牙髓间充质干细胞的试剂盒
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
FR3062213B1 (fr) * 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582790A (en) 1983-02-15 1986-04-15 Wisconsin Alumni Research Foundation Monoclonal antibody to angiotension-converting enzyme and methods of preparing and using same
AU721129B2 (en) * 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
WO1998021334A2 (en) 1996-11-13 1998-05-22 Morphogenesis, Inc. Antibody mg1 recognizing a small subset of human hematopoietic cells
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell

Also Published As

Publication number Publication date
EP1432991A1 (en) 2004-06-30
US7718376B2 (en) 2010-05-18
JP2004538490A (ja) 2004-12-24
ES2381183T3 (es) 2012-05-23
ATE543098T1 (de) 2012-02-15
JP4922548B2 (ja) 2012-04-25
EP1432991B1 (en) 2012-01-25
IL160394A (en) 2011-07-31
WO2003016916A1 (en) 2003-02-27
IL160394A0 (en) 2004-07-25
AUPR703601A0 (en) 2001-09-06
US20060088890A1 (en) 2006-04-27
AU2002355970B2 (en) 2008-10-23
CA2457632A1 (en) 2003-02-27
EP1432991A4 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
CA2457632C (en) Identification and isolation of somatic stem cells and uses thereof
AU2002355970A1 (en) Identification and isolation of somatic stem cells and uses thereof
Yin et al. AC133, a novel marker for human hematopoietic stem and progenitor cells
EP2324359B1 (en) Use of heat shock protein 90-beta as marker for the identification and/or enrichment of adult multipotential mesenchymal precursor cells
EP0787181B1 (en) Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5814440A (en) Methods of obtaining compositions enriched for hematopoietic stem cells, antibodies for use therein, compositions derived therefrom and methods of use thereof
Altieri et al. Identification of effector cell protease receptor-1. A leukocyte-distributed receptor for the serine protease factor Xa.
WO1996015228A1 (en) Method of purifying a population of cells enriched for hematopoietic stem cells
CA1170593A (en) Hybrid cell line for producing monoclonal antibody to human cytotoxic and suppressor t cells, antibody, and methods
Gindraux et al. Human and rodent bone marrow mesenchymal stem cells that express primitive stem cell markers can be directly enriched by using the CD49a molecule
JPWO2003027281A1 (ja) 骨格筋間質由来多分化能幹細胞
ES2306876T3 (es) Marcador para celulas madre y su uso.
US7732126B2 (en) Integrin CD18 is a novel stromal stem cell marker and functions to promote osteogenesis
CA2059824A1 (en) Hybridomas and monoclonal antibodies that inhibit anti-cd3-stimulated t cell proliferation
Ramshaw et al. Monoclonal antibody BB9 raised against bone marrow stromal cells identifies a cell-surface glycoprotein expressed by primitive human hemopoietic progenitors
Barrande et al. Isolation and characterization of two new monoclonal antibodies against the CD34 molecule
US4637983A (en) Hybrid cell line for producing monoclonal antibody to human cytotoxic and suppressor T cells, antibody, and methods
Olweus et al. AC133, a novel marker for human hematopoietic stem and progenitor
SK281965B6 (sk) Monoklonálna protilátka inhibujúca zachytávanie krvotvorných kmeňových buniek a hybridóm
JP3043629B2 (ja) 抗体１０３ｂ２
Class et al. Patent application title: MONOCLONAL ANTIBODY STRO-4 Inventors: Stan Gronthos (Adelaide, AU) Andrew Christopher William Zannettino (Highbury, AU) Assignees: MESOBLAST, INC.
WO1996040874A1 (en) Methods for obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180815